According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

Mile Brujic, OD, FAAO, discusses the use of specialty lenses vs glasses in some patients, as well as approaches to managing the symptoms of dry eye disease.

Mile Brujic, OD, FAAO, presents a patient case of a 67-year-old woman with dry eye disease and a history of radial keratotomy (RK) surgery.

Mile Brujic, OD, FAAO, shares considerations from a patient case, highlighting diagnostic tools in dry eye disease as well as the ability of the patient to use medication.

Mile Brujic, OD, FAAO, presents the case of a 42-year-old female patient with dry eye disease who has discomfort using eyedrops.

The complement C5 inhibitor significantly reduced GA progression.

Catch up on what happened in optometry during the week of September 11-September 15.

Documenting the visual effects and simplifying visual life.

Prevention should be at the forefront of the discussion.

Jessica Crooker, OD, sits down with Optometry Times to discuss common pitfalls optometrists run into when fitting multifocal contact lenses and how to avoid them.

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference agenda will mean for clinicians and addresses the anticipated increased patient volume.

What 1 doctor did to increase their capture rate to over 80%.